KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBT Margin (2016 - 2025)

Historic EBT Margin for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to 6.38%.

  • TherapeuticsMD's EBT Margin rose 1100300.0% to 6.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.36%, marking a year-over-year increase of 2516100.0%. This contributed to the annual value of 133.05% for FY2024, which is 4615700.0% up from last year.
  • Latest data reveals that TherapeuticsMD reported EBT Margin of 6.38% as of Q3 2025, which was up 1100300.0% from 57.25% recorded in Q2 2025.
  • TherapeuticsMD's 5-year EBT Margin high stood at 268.5% for Q4 2021, and its period low was 4273.85% during Q2 2022.
  • Its 5-year average for EBT Margin is 854.93%, with a median of 198.24% in 2021.
  • Its EBT Margin has fluctuated over the past 5 years, first crashed by -40884200bps in 2022, then skyrocketed by 37214500bps in 2023.
  • Over the past 5 years, TherapeuticsMD's EBT Margin (Quarter) stood at 268.5% in 2021, then crashed by -74bps to 70.67% in 2022, then plummeted by -547bps to 315.54% in 2023, then soared by 104bps to 12.44% in 2024, then crashed by -49bps to 6.38% in 2025.
  • Its last three reported values are 6.38% in Q3 2025, 57.25% for Q2 2025, and 169.97% during Q1 2025.